Download PDF
Semin Thromb Hemost 2001; 27(5): 489-494
DOI: 10.1055/s-2001-17956
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Cellular Effects of Factor Xa on Vascular Smooth Muscle Cells-Inhibition by Heparins?

Ellen Bretschneider1 , Karsten Schrör2
  • 1Center for Vascular Biology and Medicine Erfurt, Fredrich-Schiller-University Jena, Erfurt, Germany
  • 2Institute of Pharmacology and Clinical Pharmacology; Heinrich-Heine-University, Düsseldorf, Germany
Further Information

Publication History

Publication Date:
22 October 2001 (online)

    Permissions and Reprints

ABSTRACT

In addition to its key function as a clotting enzyme, factor Xa (FXa) also elicits cellular effects. In cultured human venous smooth muscle cells (SMCs), FXa induced a mitogenic response that was independent of thrombin and platelet-derived growth factor (PDGF). Unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) (enoxaparin) inhibited the mitogenic effects of FXa, thrombin and fetal calf serum (FCS), but did not reduce mitogenesis induced by PDGF. Similarly, both UFH and LMWH inhibited the activation of extracellular signal-regulated kinase (ERK-1/2) by FXa, thrombin and FCS, but not by PDGF. This indicates that heparins can influence cellular signaling in SMC via an antithrombin-II (AT-III)-independent mechanism. The inhibition of ERK-1/2 correlated with the inhibition of mitogenesis by the heparins. Thus, the inhibition of ERK-1/2 phosphorylation by heparins might predict an antimitogenai response in this system.

KEYWORD

Unfractionated heparin (UFH) - low-molecular-weight heparin (LMWH) - vascular smooth muscle cells - mitogenesis - ERK-1/2

REFERENCES

  • 1 Taubman M B, Marmur J D, Rosenfield C-L. Agonist-mediated tissue-factor expression in cultured vascular smooth muscle cells.  J Clin Invest . 1993;  91 547-552
    PubMedGoogle Scholar
  • 2 Hatakeyama K, Asada Y, Marutsuka K. Localization and activity of tissue factor in human aortic atherosclerotic lesions.  Atherosclerosis . 1997;  133 213-219
    CrossrefPubMedGoogle Scholar
  • 3 Xuereb J M, Herbert J M, Sie P, Boneu B, Constans J. Effects of heparin and related sulfated polysaccharides on tissue factor expression induced by mitogenic and non-mitogenic factors in human vascular smooth muscle cells.  Thromb Haemost . 1999;  81 151-156
    PubMedGoogle Scholar
  • 4 Xuereb J M, Sie P, Boneu B, Constans J. Inhibition of tissue factor synthesis by disruption of ERK kinases and PKC signaling pathways in human vascular SMCs.  Thromb Haemost . 2000;  84 129-136
    PubMedGoogle Scholar
  • 5 Hoover R L, Rosenberg R, Haering W, Karnovsky M J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies.  Circ Res . 1980;  47 578-583
    PubMedGoogle Scholar
  • 6 Daum G, Hedin U, Wang Y, Wang T, Clowes A W. Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells.  Circ Res . 1997;  81 17-23
    PubMedGoogle Scholar
  • 7 Kalmes A, Vesti B R, Daum G, Abraham J A, Clowes A W. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor.  Circ Res . 2000;  87 92-98
    PubMedGoogle Scholar
  • 8 Gasic G P, Arenas C P, Gasic T B, Gasic G J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells.  Proc Natl Acad Sci USA . 1992;  89 2317-2320
    CrossrefPubMedGoogle Scholar
  • 9 Ko F N, Yang Y C, Huang S C, Ou J T. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat.  J Clin Invest . 1996;  98 1493-1501
    PubMedGoogle Scholar
  • 10 Hérbert J-M, Bono F, Hérault J. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.  J Clin Invest . 1998;  101 993-1000
    PubMedGoogle Scholar
  • 11 Furie B, Furie B C. The molecular basis of blood coagulation.  Cell . 1988;  53 505-518
    CrossrefPubMedGoogle Scholar
  • 12 Bretschneider E, Braun M, Fischer A. Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells.  Thromb Haemost . 2000;  84 499-505
    PubMedGoogle Scholar
  • 13 Nicholson A C, Nachman R L, Altieri D C. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa.  J Biol Chem . 1996;  271 28407-28413
    CrossrefPubMedGoogle Scholar
  • 14 Zaman G JR, Conway E M. The elusive factor Xa receptor: failure to detect transcripts that correspond to the published sequence of EPR-1.  Blood . 2000;  96 145-148
    PubMedGoogle Scholar
  • 15 Camerer E, Rottingen J-A, Gjernes E. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene.  J Biol Chem . 1999;  274 32225-32233
    CrossrefPubMedGoogle Scholar
  • 16 Castellot J J, Wong K, Herman B. Binding and internalization of heparin by vascular smooth muscle cells.  J Cell Physiol . 1985;  124 13-20
    CrossrefPubMedGoogle Scholar
  • 17 Stöhr S, Meyer T, Smolenski A, Kreuzer H, Buchwald A B. Effects of heparin on aortic versus venous smooth muscle cells: Similar binding with different rates of [3H]-thymidine incorporation.  J Cardiovasc Pharmacol . 1995;  25 782-788
    PubMedGoogle Scholar
  • 18 Patel M K, Refson J S, Schachter M, Hughes A D. Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.  Br J Pharmacol . 1999;  127 361-368
    CrossrefPubMedGoogle Scholar
  • 19 Igura T, Kawata S, Miyagawa J. Expression of heparin-binding epidermal growth factor-like growth factor in neointimal cells induced by balloon injury in rat carotid arteries.  Arterioscler Thromb Vasc Biol . 1996;  16 1524-1531
    PubMedGoogle Scholar
  • 20 Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor.  Biochim Biophys Acta . 1997;  1333 F179-F199
    PubMedGoogle Scholar
  • 21 Clowes A W, Karnovsky M J. Suppression by heparin of smooth muscle cell proliferation in injured arteries.  Nature . 1977;  265 625-626
    CrossrefPubMedGoogle Scholar
  • 22 Kohler T R, Kirkman T, Clowes A W. Effect of heparin on adaptation of vein grafts to the arterial circulation.  Arteriosclerosis . 1989;  9 523-528
    PubMedGoogle Scholar
  • 23 Hirsch G M, Karnovsky M J. Inhibition of vein graft intimal proliferative lesions in the rat by heparin.  Am J Pathol . 1991;  139 581-587
    PubMedGoogle Scholar
  • 24 Hammerle H, Betz E, Herr D. Human endothelial cells are stimulated and vascular smooth muscle cells are inhibited in their proliferation and migration by heparins.  Vasa J Vasc Dis . 1991;  20 207-215
    PubMedGoogle Scholar
  • 25 Pukac L A, Carter J E, Ottlinger M E, Karnovsky M J. Mechanisms of inhibition by heparin of PDGF stimulated MAP-kinase activation in vascular smooth muscle cells.  J Cell Physiol . 1997;  172 69-78
    CrossrefPubMedGoogle Scholar
  • 26 Templeton D M, Zhao Y, Fan M Y. Heterogeneity in the response of vascular smooth muscle to heparin: altered signaling in heparin-resistant cells.  Cardiovasc Res . 2000;  45 503-512
    CrossrefPubMedGoogle Scholar
  • 27 Varty K, Allen K E, Jones L. The influence of low molecular weight heparin on neointimal proliferation in cultured human saphenous vein.  Eur J Vasc Surg . 1994;  8 174-178
    PubMedGoogle Scholar
  • 28 Guyton J R, Rosenberg R D, Clowes A W, Karnovsky M J. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin.  Circ Res . 1980;  46 625-634
    PubMedGoogle Scholar
  • 29 Pukac L A, Hirsch G M, Lormeau J. Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo.  Am J Pathol . 1991;  139 1501-1509
    PubMedGoogle Scholar
  • 30 Hérbert J M, Lamarche I, Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor. Effect of heparin.  FEBS Lett . 1992;  301 155-158
    CrossrefPubMedGoogle Scholar
  • 31 Cambria R P, Ivarsson B L, Fallon J T, Abbott W M. Heparin fails to suppress intimal proliferation in experimental vein grafts.  Surgery . 1992;  111 424-429
    PubMedGoogle Scholar
  • 32 Geary R L, Koyama N, Wang T W, Vergel S, Clowes A W. Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries: the role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation.  Circulation . 1995;  91 2972-2981
    PubMedGoogle Scholar
  • 33 Ottlinger M E, Pukac L A, Karnovsky M J. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells.  J Biol Chem . 1993;  268 19173-19176
    PubMedGoogle Scholar
  • 34 Hedin U, Daum G, Clowes A W. Heparin inhibits thrombin-induced mitogen-activated protein kinase signaling in arterial smooth muscle cells.  J Vasc Surg . 1998;  27 512-520
    PubMedGoogle Scholar
  • 35 Pukac L, Huangpu J, Karnovsky M J. Platelet-derived growth factor-BB, insulin-like growth factor-I and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration.  Exp Cell Res . 1998;  242 548-560
    CrossrefPubMedGoogle Scholar
  • 36 Refson J S, Schachter M, Patel M K. Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells.  Circulation . 1998;  97 2506-2510
    PubMedGoogle Scholar
  • 37 Sindermann J R, March K L. Heparin responsiveness in vitro as a prognostic tool for vascular graft stenosis. A tale of two cell types?.  Circulation . 1998;  97 2486-2490
    PubMedGoogle Scholar
      >